Evidence map›Paper›PMID 35822768›Full record

ReviewBiotech (Basel (Switzerland))2021

Applications of CRISPR-Cas9 as an Advanced Genome Editing System in Life Sciences.

Kamand Tavakoli, Alireza Pour-Aboughadareh, Farzad Kianersi, Peter Poczai, Alireza Etminan, Lia Shooshtari

Abstract readReview
In one paragraph

Review in Biotech (Basel (Switzerland)), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Amyloids and the Heart: An Update.Journal of clinical medicine · 2024
    Review
  10. Article
  11. Review
  12. Comparison of CRISPR-MAD7 and CRISPR-Cas9 for Gene Disruptions inJournal of fungi (Basel, Switzerland) · 2024
    Article
  13. Review
  14. Review
  15. Article
  16. Assessment of CRISPRa-mediatedFrontiers in bioengineering and biotechnology · 2024
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kamand TavakoliDepartment of Medical Laboratory Science, Kermanshah Branch, Islamic Azad University, Kermanshah P.O. Box 6718997551, Iran.
Alireza Pour-AboughadarehSeed and Plant Improvement Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj P.O. Box 3158854119, Iran.ORCID 0000-0001-5782-5327
Farzad KianersiDepartment of Agronomy and Plant Breeding, Faculty of Agriculture, Bu-Ali Sina University, Hamedan P.O. Box 6517838695, Iran.ORCID 0000-0002-2692-9876
Peter PoczaiBotany Unit, Finnish Museum of Natural History, University of Helsinki, P.O. Box 7, FI-00014 Helsinki, Finland.ORCID 0000-0002-0107-1068
Alireza EtminanDepartment of Plant Breeding and Biotechnology, Kermanshah Branch, Islamic Azad University, Kermanshah P.O. Box 6718997551, Iran.
Lia ShooshtariDepartment of Plant Breeding and Biotechnology, Kermanshah Branch, Islamic Azad University, Kermanshah P.O. Box 6718997551, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted nucleases are powerful genomic tools to precisely change the target genome of living cells, controlling functional genes with high exactness. The clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9) genome editing system has been identified as one of the most useful biological tools in genetic engineering that is taken from adaptive immune strategies for bacteria. In recent years, this system has made significant progress and it has been widely used in genome editing to create gene knock-ins, knock-outs, and point mutations. This paper summarizes the application of this system in various biological sciences, including medicine, plant science, and animal breeding.

Indexed as

agricultureanimal scienceCas proteinsCRISPR systemhuman disease

Identifiers

PMID35822768
PMCPMC9245484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.